Aarti Drugs Limited (BOM:524348)
India · Delayed Price · Currency is INR 500.30
+50.10 (11.13%)
At close: Nov 9, 2026
Aarti Drugs Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 28,510 | 25,653 | 23,870 | 25,286 | 27,161 | 24,886 |
Other Revenue | -0.1 | - | - | - | - | 0 |
| 28,510 | 25,653 | 23,870 | 25,286 | 27,161 | 24,886 | |
Revenue Growth | 15.12% | 7.47% | -5.60% | -6.90% | 9.14% | 15.49% |
Cost of Revenue | 17,880 | 16,431 | 15,569 | 16,970 | 19,102 | 17,022 |
Gross Profit | 10,630 | 9,223 | 8,301 | 8,316 | 8,058 | 7,865 |
Selling, General & Admin | 1,421 | 1,324 | 1,141 | 1,047 | 933.07 | 840.53 |
Other Operating Expenses | 5,335 | 4,807 | 4,289 | 4,104 | 4,069 | 3,640 |
Operating Expenses | 7,491 | 6,800 | 5,988 | 5,666 | 5,505 | 4,981 |
Operating Income | 3,139 | 2,422 | 2,313 | 2,650 | 2,553 | 2,884 |
Interest Expense | -362.95 | -337.15 | -358.73 | -335.15 | -332.93 | -207.48 |
Interest & Investment Income | 11.69 | 11.69 | 124.09 | 24.97 | 7.02 | 23.16 |
Other Non Operating Income (Expenses) | 12.11 | 12.2 | 39.51 | 15.33 | 14.92 | 0 |
EBT Excluding Unusual Items | 2,800 | 2,109 | 2,118 | 2,355 | 2,242 | 2,700 |
Other Unusual Items | -20.9 | - | - | - | - | - |
Pretax Income | 2,779 | 2,109 | 2,118 | 2,355 | 2,242 | 2,700 |
Income Tax Expense | 491.94 | 159.64 | 436.74 | 639.37 | 578.25 | 649.59 |
Earnings From Continuing Operations | 2,287 | 1,949 | 1,681 | 1,716 | 1,664 | 2,050 |
Minority Interest in Earnings | 1.39 | -0.2 | 0.62 | -1.73 | -0.48 | 0.43 |
Net Income | 2,288 | 1,949 | 1,682 | 1,714 | 1,663 | 2,050 |
Net Income to Common | 2,288 | 1,949 | 1,682 | 1,714 | 1,663 | 2,050 |
Net Income Growth | 14.94% | 15.91% | -1.90% | 3.07% | -18.89% | -26.88% |
Shares Outstanding (Basic) | 91 | 91 | 91 | 92 | 93 | 93 |
Shares Outstanding (Diluted) | 91 | 91 | 91 | 92 | 93 | 93 |
Shares Change | 4.94% | - | -0.72% | -0.72% | - | -0.64% |
EPS (Basic) | 25.07 | 21.36 | 18.42 | 18.65 | 17.96 | 22.14 |
EPS (Diluted) | 25.06 | 21.36 | 18.35 | 18.65 | 17.96 | 22.14 |
EPS Growth | 9.47% | 16.38% | -1.58% | 3.82% | -18.89% | -26.41% |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | -23.33 | 802.17 | 674.22 | 1,326 | -314.97 | -815.61 |
Free Cash Flow Per Share | -0.26 | 8.79 | 7.39 | 14.42 | -3.40 | -8.81 |
Dividend Per Share | - | 2.000 | 1.000 | 1.000 | 1.000 | 1.000 |
Dividend Growth | - | 100.00% | 0% | 0% | 0% | -60.00% |
Gross Margin | 37.28% | 35.95% | 34.77% | 32.89% | 29.67% | 31.60% |
Operating Margin | 11.01% | 9.44% | 9.69% | 10.48% | 9.40% | 11.59% |
Profit Margin | 8.03% | 7.60% | 7.04% | 6.78% | 6.12% | 8.24% |
Free Cash Flow Margin | -0.08% | 3.13% | 2.83% | 5.24% | -1.16% | -3.28% |
EBITDA | 3,825 | 3,043 | 2,842 | 3,140 | 3,028 | 3,353 |
EBITDA Margin | 13.41% | 11.86% | 11.91% | 12.42% | 11.15% | 13.47% |
D&A For EBITDA | 685.65 | 620.85 | 529.61 | 489.77 | 475.43 | 469.4 |
EBIT | 3,139 | 2,422 | 2,313 | 2,650 | 2,553 | 2,884 |
EBIT Margin | 11.01% | 9.44% | 9.69% | 10.48% | 9.40% | 11.59% |
Effective Tax Rate | 17.70% | 7.57% | 20.62% | 27.15% | 25.79% | 24.06% |
Revenue as Reported | 28,564 | 25,677 | 24,034 | 25,326 | 27,182 | 25,000 |
Advertising Expenses | - | 27.37 | 17.91 | 23.3 | 11.67 | 13.5 |